A budget impact analysis of 15- or 20- valent pneumococcal conjugate vaccine use in all US adults aged 50–64 years old compared to those with high-risk conditions from US payer perspective
Abstract Background In 2023, the US CDC recommended 20-valent pneumococcal conjugate vaccine (PCV20) or 15-valent pneumococcal conjugate vaccine (PCV15) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all adults aged 65-years and older and those aged 19–64 years old with chron...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-06-01
|
| Series: | BMC Public Health |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12889-025-22827-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850136856471011328 |
|---|---|
| author | Nirma Khatri Vadlamudi Chyongchiou J. Lin Angela R. Wateska Richard K. Zimmerman Kenneth J. Smith |
| author_facet | Nirma Khatri Vadlamudi Chyongchiou J. Lin Angela R. Wateska Richard K. Zimmerman Kenneth J. Smith |
| author_sort | Nirma Khatri Vadlamudi |
| collection | DOAJ |
| description | Abstract Background In 2023, the US CDC recommended 20-valent pneumococcal conjugate vaccine (PCV20) or 15-valent pneumococcal conjugate vaccine (PCV15) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all adults aged 65-years and older and those aged 19–64 years old with chronic conditions. However, there is substantial pneumococcal disease burden in healthy adults aged 50–64 years, particularly in Black adults, who are likely to benefit from vaccination. This study assesses the financial impact of introducing routine PCV15 or PCV20 in US adults aged 50–64 years. Objective To evaluate the budget impact of introducing PCV20 or PCV15/PPSV23 use in adults aged 50–64 years old compared to vaccinating only those with high-risk conditions for pneumococcal disease. Methods A budget impact model was developed over a 3-year time horizon to compare PCV20 versus PCV15/PPSV23 from the US payer perspective. Outcomes and costs of pneumococcal disease among US adults aged 50–64 years and those with underlying conditions were projected using a Markov decision model. Results Incorporating either PCV20 or PCV15/PPSV23 vaccines in routine vaccination programs for adults aged 50–64 years compared to vaccinating only adults with chronic conditions had an incremental budget impact of $6.5 and $9 billion, respectively, over three years. Budgetary impact was sensitive to number of vaccine doses, cost of vaccine per dose, vaccine coverage proportion and pneumococcal treatment cost across the overall population and sub-groups. Routine vaccination of 50-64-year-old age group was more economically favorable in Black adults sub-group analyses. |
| format | Article |
| id | doaj-art-f9b1779bb41e4f2b8167575c26877df8 |
| institution | OA Journals |
| issn | 1471-2458 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Public Health |
| spelling | doaj-art-f9b1779bb41e4f2b8167575c26877df82025-08-20T02:31:00ZengBMCBMC Public Health1471-24582025-06-012511810.1186/s12889-025-22827-9A budget impact analysis of 15- or 20- valent pneumococcal conjugate vaccine use in all US adults aged 50–64 years old compared to those with high-risk conditions from US payer perspectiveNirma Khatri Vadlamudi0Chyongchiou J. Lin1Angela R. Wateska2Richard K. Zimmerman3Kenneth J. Smith4Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of FloridaCollege of Nursing, The Ohio State UniversityDepartment of Medicine, University of PittsburghDepartment of Family Medicine, University of PittsburghDepartment of Medicine, University of PittsburghAbstract Background In 2023, the US CDC recommended 20-valent pneumococcal conjugate vaccine (PCV20) or 15-valent pneumococcal conjugate vaccine (PCV15) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all adults aged 65-years and older and those aged 19–64 years old with chronic conditions. However, there is substantial pneumococcal disease burden in healthy adults aged 50–64 years, particularly in Black adults, who are likely to benefit from vaccination. This study assesses the financial impact of introducing routine PCV15 or PCV20 in US adults aged 50–64 years. Objective To evaluate the budget impact of introducing PCV20 or PCV15/PPSV23 use in adults aged 50–64 years old compared to vaccinating only those with high-risk conditions for pneumococcal disease. Methods A budget impact model was developed over a 3-year time horizon to compare PCV20 versus PCV15/PPSV23 from the US payer perspective. Outcomes and costs of pneumococcal disease among US adults aged 50–64 years and those with underlying conditions were projected using a Markov decision model. Results Incorporating either PCV20 or PCV15/PPSV23 vaccines in routine vaccination programs for adults aged 50–64 years compared to vaccinating only adults with chronic conditions had an incremental budget impact of $6.5 and $9 billion, respectively, over three years. Budgetary impact was sensitive to number of vaccine doses, cost of vaccine per dose, vaccine coverage proportion and pneumococcal treatment cost across the overall population and sub-groups. Routine vaccination of 50-64-year-old age group was more economically favorable in Black adults sub-group analyses.https://doi.org/10.1186/s12889-025-22827-9PneumococcalBudget impact analysesVaccineUSAdults |
| spellingShingle | Nirma Khatri Vadlamudi Chyongchiou J. Lin Angela R. Wateska Richard K. Zimmerman Kenneth J. Smith A budget impact analysis of 15- or 20- valent pneumococcal conjugate vaccine use in all US adults aged 50–64 years old compared to those with high-risk conditions from US payer perspective BMC Public Health Pneumococcal Budget impact analyses Vaccine US Adults |
| title | A budget impact analysis of 15- or 20- valent pneumococcal conjugate vaccine use in all US adults aged 50–64 years old compared to those with high-risk conditions from US payer perspective |
| title_full | A budget impact analysis of 15- or 20- valent pneumococcal conjugate vaccine use in all US adults aged 50–64 years old compared to those with high-risk conditions from US payer perspective |
| title_fullStr | A budget impact analysis of 15- or 20- valent pneumococcal conjugate vaccine use in all US adults aged 50–64 years old compared to those with high-risk conditions from US payer perspective |
| title_full_unstemmed | A budget impact analysis of 15- or 20- valent pneumococcal conjugate vaccine use in all US adults aged 50–64 years old compared to those with high-risk conditions from US payer perspective |
| title_short | A budget impact analysis of 15- or 20- valent pneumococcal conjugate vaccine use in all US adults aged 50–64 years old compared to those with high-risk conditions from US payer perspective |
| title_sort | budget impact analysis of 15 or 20 valent pneumococcal conjugate vaccine use in all us adults aged 50 64 years old compared to those with high risk conditions from us payer perspective |
| topic | Pneumococcal Budget impact analyses Vaccine US Adults |
| url | https://doi.org/10.1186/s12889-025-22827-9 |
| work_keys_str_mv | AT nirmakhatrivadlamudi abudgetimpactanalysisof15or20valentpneumococcalconjugatevaccineuseinallusadultsaged5064yearsoldcomparedtothosewithhighriskconditionsfromuspayerperspective AT chyongchioujlin abudgetimpactanalysisof15or20valentpneumococcalconjugatevaccineuseinallusadultsaged5064yearsoldcomparedtothosewithhighriskconditionsfromuspayerperspective AT angelarwateska abudgetimpactanalysisof15or20valentpneumococcalconjugatevaccineuseinallusadultsaged5064yearsoldcomparedtothosewithhighriskconditionsfromuspayerperspective AT richardkzimmerman abudgetimpactanalysisof15or20valentpneumococcalconjugatevaccineuseinallusadultsaged5064yearsoldcomparedtothosewithhighriskconditionsfromuspayerperspective AT kennethjsmith abudgetimpactanalysisof15or20valentpneumococcalconjugatevaccineuseinallusadultsaged5064yearsoldcomparedtothosewithhighriskconditionsfromuspayerperspective AT nirmakhatrivadlamudi budgetimpactanalysisof15or20valentpneumococcalconjugatevaccineuseinallusadultsaged5064yearsoldcomparedtothosewithhighriskconditionsfromuspayerperspective AT chyongchioujlin budgetimpactanalysisof15or20valentpneumococcalconjugatevaccineuseinallusadultsaged5064yearsoldcomparedtothosewithhighriskconditionsfromuspayerperspective AT angelarwateska budgetimpactanalysisof15or20valentpneumococcalconjugatevaccineuseinallusadultsaged5064yearsoldcomparedtothosewithhighriskconditionsfromuspayerperspective AT richardkzimmerman budgetimpactanalysisof15or20valentpneumococcalconjugatevaccineuseinallusadultsaged5064yearsoldcomparedtothosewithhighriskconditionsfromuspayerperspective AT kennethjsmith budgetimpactanalysisof15or20valentpneumococcalconjugatevaccineuseinallusadultsaged5064yearsoldcomparedtothosewithhighriskconditionsfromuspayerperspective |